Quality of Life (Qol) Results from the Phase 3 Revel Study of Ramucirumab + Docetaxel (Ram + Dtx) Versus Placebo + Docetaxel (Pl + Dtx) in Advanced/Metastatic Nsclc Patients (Pts) with Progression After Platinum Based Chemotherapy
Articles > Article · 2014
Authors: E.B. Garon, T. Ciuleanu, O. Arrieta, K. Prabhash, K.N. Syrigos, Tuncay GÖKSEL, K. Park, R. Kowalyszyn, J. Pikiel, C. Lewanski, M. Thomas, S. Dakhil, J. Kim, N. Karaseva, S. Yurasov, A. Zimmermann, G. Cuyun Carter, M. Reck, F. Cappuzzo, M. Perol
Annals of Oncology, International, WoS, 2014, vol 25, pp iv445-iv445